According to Herbert Meltzer, MD, a professor of psychiatry and pharmacology at Vanderbilt University and a consultant to its developer, ACADIA Pharmaceuticals, Inc., pimavanserin is aselective 5 HT2a inverse agonist - an antagonistthat also blocks endogenous basal activity in the area of the serotonin Zareceptor. [...] while it does not directly affect dopamine receptors, it has powerful effects on dopamine, glutamate, and GABA release through blockade of the stimulatory effects of dopamine on the affinity to neurons that release these key neurotransmittcrs.
More treatment options emerge William M Glazer Behavioral Healthcare; Jun 2009; 29, 6; Docstoc pg. 20 Reproduced with permission of the copyright own
Pages to are hidden for
"More treatment options emerge"Please download to view full document